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Karl Mårild1,2*, Johnny Ludvigsson3, Yolanda Sanz4 and Jonas F Ludvigsson1,5Abstract
Background: The infant microbiota may play a pathogenic role in coeliac disease (CD). Antibiotic treatment in
pregnancy is common and could significantly impact the infant microbiota. In this study, we aimed to investigate
the association between antibiotic exposure during pregnancy and CD in offspring.
Methods: Prospective questionnaire data on antibiotic exposure in pregnancy were available in 8729 children
participating in the All Babies in Southeast Sweden (ABIS) cohort study, and of these 46 developed CD until
December 2006. Cox regression estimated hazard ratios (HRs) for CD in the offspring among mothers exposed
to antibiotics during pregnancy, with adjustment for parent-reported diary data on breastfeeding, age at gluten
introduction and number of infections in the child’s first year of life.
Results: Of the 1836 children exposed to antibiotics during pregnancy, 12 (0.7%) children developed CD as compared
with 34/6893 (0.5%) unexposed children (HR = 1.33; 95% CI = 0.69-2.56). Risk estimates remained unchanged after
adjustment for breastfeeding, age at gluten introduction and infection load in the child’s first year of life (HR = 1.28;
95% CI = 0.66-2.48).
Conclusions: We found no statistically significant association between antibiotic exposure during pregnancy and CD
in offspring. This lack of association may either be true or the result of limited statistical power.
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Coeliac disease (CD) is a life-long autoimmune disease
occurring in 1-2% of children and adults living in
Western countries [1,2]. In CD, genetically predisposed
individuals develop small-intestinal villous atrophy in
response to dietary gluten intake [3]. In the last
decades the prevalence of CD has more than doubled,
[4] suggesting that environmental factors other than
gluten-exposure may have a significant influence on
CD development [5]. Earlier research has in particular
emphasized the importance of environmental factors
early in life, including pregnancy and the perinatal
period, [6,7] for the development of CD.
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unless otherwise stated.of the intestinal immune system, the establishment of oral
tolerance and the mucosal barrier function [8]. Likewise,
imbalances in the intestinal microbiota (dysbiosis)
are frequently related to immune dysregulation and
development of immune-mediated diseases and vice
versa. Several studies have found dysbiosis in individuals
with CD as compared with healthy controls, suggesting
that the gut microbiota may play a pathogenic role in CD
[9]. The infant gut colonization begins perinatally and is
strongly influenced by the maternal microbiota, the mode
of delivery and subsequently by the infant feeding practice
[10]. Some data also indicate that maternal antibiotic
intake in pregnancy influences the gut microbiota in the
offspring, [11] and that perturbations caused by antibiotics
in the infant [12] and adult microbiota [13,14] may persist
for several years. Antibiotics are in fact one of the
main environmental stressors that lead to the replacement
of symbiotic bacteria by otherwise under-represented
potentially pathogenic bacteria [13,15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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antibiotics. Recent data have shown a positive association
between antibiotic use during pregnancy and offspring
asthma, [18] a disease that shares potential etiological and
epidemiological traits with CD [19-21]. We have recently
shown a positive association between antibiotic use in early
childhood and subsequent CD [22]. However, there are few
data whether antibiotic exposure in pregnancy influences
the risk of CD in offspring.
Methods
In this prospective population-based cohort study we used
data from the ABIS cohort (All Babies in Southeast Sweden)
in order to examine the association between antibiotic
exposure in pregnancy and CD in the offspring.
Study population
Between October 1997 and October 1999, all parents to
babies born in southeast Sweden were invited to participate
in the ABIS cohort. Of the 21,700 babies born during the
study period, the parents of 17,055 children (78.6%) gave
their informed consent to participate. In the maternity
ward (at childbirth), parents to 16,285 children completed
a questionnaire that included questions on antibiotics use
in pregnancy, maternal education level, heath status and
first-degree heredity for CD, type 1 diabetes mellitus and
other autoimmune diseases.
Parents were asked to complete a structured study diary
during the child’s first year of life reporting infectious
diseases and feeding practice, including duration of
breastfeeding and age at gluten introduction. The
diaries were completed prospectively at home and
collected when the child was one year of age. In ourBab
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Figure 1 Flow chart study participants.main analysis we included 8729 individuals with data on
use of systemic antibiotics during pregnancy and with
complete diary data for duration of breastfeeding and time
of gluten introduction (see flow chart, Figure 1).
The parents of the study participants were slightly more
often born in Sweden and with a higher level of education,
as compared with the source population of southeast
Sweden [23]. Additional background data of the ABIS
cohort have been described elsewhere [24,25].
Coeliac disease (CD)
Data on CD were collected through contact with all
paediatric departments (n = 8) in the ABIS study area. The
majority of children with CD were identified through a
study published in 2004 [24]. In 2007–2008, we again
contacted the same paediatric departments and asked them
to report additional ABIS children with a biopsy-verified
CD (villous atrophy) diagnosed until December 1st 2006. In
addition to a biopsy suggestive of CD (Marsh grade III),
children with CD were required either to have CD-specific
antibody markers or CD-consistent symptoms that resolved
after introduction of gluten-free diet [24]. In the current
study, date of CD diagnosis equals date of first positive
small-intestinal biopsy. The ABIS population was not
actively screened for CD and therefore the children
with CD were investigated due to clinical manifestations
of possible CD.
Maternal antibiotic exposure in pregnancy
We collected questionnaire data on use of any systemic
antibiotics during pregnancy. The mothers exposed to
antibiotics were asked to specify the name on the type of
antibiotics. Mothers who were uncertain of their antibioticn=21,700 
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non-systemic antibiotics (n = 2) were excluded from
the study.
Statistical analyses
We used Cox regression to estimate Hazard Ratios
(HRs) and 95% confidence intervals (CIs) for the risk of
childhood CD according to maternal antibiotic exposure
in pregnancy.
In our main analysis (Model A, n = 8729) we used
diary data to adjust for duration of breastfeeding (0–2;
3–4; 5–6; 7–8; 9–10 and ≥11 months) and age at
gluten introduction (0–2; 3–4; 5–6; 7–8; 9–10 and
11–12 months of age) as potential confounders for CD
development [25-27].
In a second analysis (Model B, n = 8698) we also
adjusted for maternal education level (≤12 vs. >12 years)
and number of any parent-reported infectious disease in
the child’s first year of life, categorized into the following
months of age: 0–2; 3–4; 5–6; 7–8; 9–10 and 11–12
months of age. Education level has been associated with
antibiotic use [28] and may influence the risk of CD
diagnosis [29]. Also infectious load in early childhood
may be associated with subsequent CD [30]. Follow-up
began at child’s birth and ended at time of CD diagnosis
or December 1st 2006 (end of follow-up). However,
because CD only develop after gluten introduction, which
often occurs during the first year of life, we also performed
a Cox regression in which the time scale began at
one year of age until CD diagnosis or December 1st 2006
(end of follow-up).
Mode of delivery and gestational age pertain a great
impact on the infant gut colonization [10,31-33] and have
been associated with an increased risk of CD in offspring
[6,34]. In two subanalyses we therefore restricted our
data to term deliveries and children born through vaginal
delivery, respectively. We also performed stratified
analyses by infant sex and heredity for CD or type 1
diabetes mellitus.
Statistical significance was defined as 95% CIs not
including 1.0. We used SPSS version 20.0 (SPSS, Inc,
Chicago, IL) for the statistical analyses.
Post-hoc analyses
As opposed to short duration of breastfeeding, no
breastfeeding at all can have a different effect on gut
colonization. In a post-hoc analysis we therefore chose
to adjust for duration of breastfeeding splitting the
first time category (0–2 months) into: 0–6 days and
7 days-2 months (keeping 3–4 months; 5–6 months etc.).
In a second post-hoc analysis we estimated the risk of CD
in offspring according to antibiotic exposure in pregnancy
excluding children with a first-degree relative with
autoimmune disease. According to data from the at-birthquestionnaire we defined heredity for an autoimmune
disease as presence of at least one first-degree relative
with any of the following conditions: Goitre with
hypothyroidism or hyperthyroidism, Grave `s disease, per-
nicious anaemia, systemic lupus erythematosus, Addison’s
disease, any diabetes mellitus, gestational diabetes, CD,
inflammatory bowel disease or rheumatoid arthritis.
To increase the statistical power of the study, we
performed a post-hoc analysis including all 14,942
ABIS children with available data on antibiotic exposure
in pregnancy. In this post-hoc analysis we used multiple
imputation to replace missing values for infant nutrition
data. However, since the statistics software SPSS cannot
handle survival analyses with imputed data (the command
"selection variable: rule: imputation > =1" only runs in
linear regression and logistic regression), we first
examined the odds ratio (OR) for future CD in our original
dataset adjusting for infant nutrition (according to the
covariates in Model A) before using multiple imputation
to adjust infant feeding.
In a final post-hoc analysis we adjusted for the children’s
use of antibiotics during their first year of life. Data on anti-
biotic use was collected through a questionnaire when the
child was one year old. The number of antibiotic courses
used during the child’s first year of life was classified into
the following categories: no use; 1–2; 3–5; ≥6 courses of
antibiotics. Regrettably, we largely lacked data on type of
antibiotic agent used by the children.
Power calculation
At a significance level of 0.05 we had an 80% power to
detect a relative risk of 2.45 for CD in offspring to
mothers treated with antibiotics during pregnancy.
Ethics
This study was as part of the ABIS study approved by
the Research Ethics Committees of Linköping University
(Li 287–96) and Lund University (Lu 83–97). Mothers
gave their written informed consent after careful written
as well as oral information and information via videotape.
Results
Out of the 8729 children included in the study, 1836
(21%) had been exposed to antibiotics during pregnancy
(unexposed: 6893; Table 1). Type of antibiotics was only
listed in a minority of children (n = 235), with penicillin
V being the most common type of antibiotic (n = 147).
The children were followed up to December 1st 2006,
corresponding to an average age of eight years. At end
of follow-up, 46 out of 8729 children were diagnosed
with CD, yielding a baseline CD prevalence of 0.5%. Girls
made up half of the children, and the average maternal
age at delivery was close to 30 years (Table 1).
Table 1 Descriptive characteristics of individuals
according to antibiotic exposure in pregnancy
Antibiotics No antibiotics
TotalA (%) 1836 (21.0) 6893 (79.0)
Infant sex
Girls, n (%) 904 (49.2) 3342 (48.5)
Boys, n (%) 932 (50.8) 3551 (51.5)
HeredityB
Coeliac disease, n (%) 30 (1.6) 84 (1.2)
Type 1 diabetes mellitus, n (%) 56 (3.1) 155 (2.2)
Maternal characteristics
Age at delivery; mean +/− SD (years) 30.3 +/− 4.4 29.7 +/− 4.5
Maternal university educationC, n (%) 715 (39.1) 2272 (33.1)
AIndividuals with complete data on breastfeeding and gluten introduction.
BFirst-degree relative with coeliac disease/type 1 diabetes mellitus.
C>12 years of education at time of delivery.
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children developed CD, corresponding to a HR of 1.33
(95% CI = 0.69-2.56). Risk estimates did not change
more than marginally after adjustment for duration of
breastfeeding and age at gluten introduction (Model A:
adjusted HR = 1.32, 95% CI = 0.69-2.56) or when adding
first-year childhood infections and maternal education
level (Model B: adjusted HR = 1.28, 95% CI = 0.66-2.48).
We found unchanged HR:s with follow-up time starting at
time of gluten introduction (data not shown). The relative
risk estimates for CD after antibiotic exposure during
pregnancy were similar in boys and girls (Boys: adjusted
HR = 1.28; 95% CI = 0.41-3.96; Girls: adjusted HR = 1.36;
95% CI = 0.60-3.05). Moreover, antibiotic exposure during
pregnancy did not seem to favour an earlier appearance
of CD (median age at CD diagnosis was some 2 years and
9 months among both children exposed and unexposed to
antibiotics during pregnancy).Table 2 Risk of coeliac disease in offspring (follow-up from b
Antibiotics (%) No Antibiotics (%) Crude
All 12/1836 (0.7) 34/6893 (0.5)
Sex
Boys 4/932 (0.4) 12/3551 (0.3)
Girls 8/904 (0.9) 22/3342 (0.7)
Subgroups
No heredityC 9/1753 (0.5) 28/6660 (0.4)
Term deliveriesD 12/1739 (0.7) 32/6531 (0.5)
Vaginal delivery 10/1584 (0.6) 30/6063 (0.5)
AIn Model A we adjusted for duration of breastfeeding and age at gluten introducti
were included in the analyses (n varied between 7647 and 8729).
BIn Model B we adjusted for any parent-reported infection during the child’s first ye
age at gluten introduction. Children with complete data on breastfeeding, gluten in
between 7622 and 8698).
CExcluding individuals with a first-degree relative with celiac disease (n = 105), type
DFull-term, ≥37 gestational weeks.
Hazard ratios (HR) estimated through Cox regression. Follow-up from birth.Some 316 children had a first-degree relative with
either CD (n = 105) or type 1 diabetes mellitus (n = 202) or
with both CD and type 1 diabetes (n = 9). Restricting
our data to children without heredity for CD and type
1 diabetes did not change our risk estimates (adjusted
HR = 1.22; 95% CI = 0.58-2.59). Neither did the risk
estimates change appreciably when we restricted our data
to children born full-term (n = 8270 [94.7%]) or with
a vaginal delivery (n = 7647 [87,6%]) (Table 2).
Because CD only develops after gluten introduction
(typically occurring within the first year of life), we
also performed a number of pre-planned Cox regression
analyses in which the time scale began at one year of age,
thereby excluding six children diagnosed with CD before
that age. Antibiotic exposure during pregnancy was not
significantly associated with CD in offspring diagnosed
after age one year (adjusted HR = 1.42; 95% CI = 0.71-2.83).
The risk estimates for CD diagnosed after age one year
stratified by sex and restricted to children with no heredity
for CD and type 1 diabetes are presented in Table 3.
Post-hoc analyses
In our main analysis we identified 64 children with less
than 7 days of breastfeeding. In a post-hoc analysis adjust-
ing for no breastfeeding (duration <7 days), age at gluten
introduction, infectious load in the first year of life and
maternal education level we found largely unchanged risk
estimates (adjusted HR = 1.29; 95% CI = 0.66-2.49).
Finally, we excluded children with first-degree relatives
with any autoimmune disease (remaining n = 7785 [89,2%];
HR = 1.40; 95% CI = 0.65-2.99).
To address the issue of low statistical power we per-
formed a post-hoc analysis including all 14,942 children
with available data on antibiotic exposure in pregnancy.
We used multiple imputation to replace missing values for
infant nutrition data. However, since the statistics softwareirth) according to antibiotic exposure in pregnancy
HR; 95% CI Adjusted HR; 95% CIA Adjusted HR; 95% CIB
1.33; 0.69-2.56 1.32; 0.69-2.56 1.28; 0.66-2.48
1.27; 0.41-3.94 1.28; 0.41-3.96 1.37; 0.44-4.27
1.35; 0.60-3.02 1.36; 0.60-3.05 1.21; 0.53-2.73
1.22; 0.58-2.59 1.22; 0.58-2.59 1.16; 0.55-2.47
1.41; 0.73-2.74 1.41; 0.73-2.74 1.37; 0.70-2.66
1.28; 0.63-2.61 1.28; 0.63-2.62 1.25; 0.61-2.56
on. Children with complete data on breastfeeding and gluten introduction
ar of life, maternal education level as well as duration of breastfeeding and
troduction as well as education level were included in the analyses (n varied
1 diabetes mellitus (n = 202) or both celiac disease and type 1 diabetes (n = 9).
Table 3 Risk of coeliac disease in offspring (follow-up from one year of age) according to antibiotic exposure in
pregnancy
Antibiotics (%) No Antibiotics (%) Crude HR; 95% CI Adjusted HR; 95% CIA Adjusted HR; 95% CIB
All 11/1835 (0.6) 29/6888 (0.4) 1.43; 0.71-2.86 1.42; 0.71-2.83 1.37; 0.68-2.76
Sex
Boys 4/932 (0.4) 8/3547 (0.2) 1.90; 0.57-6.32 1.91; 0.58-6.35 2.00; 0.60-6.66
Girls 7/903 (0.8) 21/3341 (0.6) 1.24; 0.53-2.91 1.24; 0.53-2.92 1.13; 0.48-2.67
Subgroups
No heredityC 8/1752 (0.5) 24/6656 (0.4) 1.27; 0.57-2.82 1.26; 0.57-2.81 1.21;0.54-2.70
Term deliveriesD 11/1738 (0.6) 27/6526 (0.4) 1.53; 0.76-3.09 1.52; 0.76-3.07 1.48; 0.73-2.99
Vaginal delivery 9/1583 (0.6) 25/6058 (0.4) 1.38; 0.64-2.96 1.37; 0.64-2.94 1.34; 0.62-2.88
AIn Model A we adjusted for duration of breastfeeding and age at gluten introduction. Children with complete data on breastfeeding and gluten introduction
were included in the analyses (n varied between 7641 and 8723).
BIn Model B we adjusted for any parent-reported infection during the child’s first year of life, education level as well as duration of breastfeeding and age at gluten
introduction. Children with complete data on breastfeeding, gluten introduction as well as education level were included in the analyses (n varied between 7616
and 8692).
CExcluding individuals with a first-degree relative with celiac disease (n = 105), type 1 diabetes mellitus (n = 202) or both celiac disease and type 1 diabetes (n = 9).
DFull-term, ≥37 gestational weeks.
Hazard ratios (HR) estimated through Cox regression. Follow-up from one year of age.
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we first examined the OR for future CD in our original
dataset adjusting for infant nutrition (maternal antibiotics:
OR for offspring CD = 1.32; 95% CI = 0.68-2.56). Using
multiple imputation when adjusting for infant feeding
did not change the risk estimate more than marginally
(OR = 1.10; 95% CI = 0.64-1.89).
In a post-hoc analysis, including 6773 children with
complete diary data and available data on use of antibiotics
during the first year of life, we found only marginally
changed risk estimates for CD (adjusted HR = 1.65;
95% CI = 0.83-3.28). The association between CD and use
of antibiotics during the child’s first year of life has been
presented in Additional file 1, Table A1.
Discussion
In this cohort study, we examined the association between
maternal use of antibiotics in pregnancy and risk of CD in
the offspring. The rationale for this study was the increasing
amount of data indicating that the maternal intestinal
microbiota in pregnancy influences the foetal and infant
immune system development [35]. However, we found no
statistically significant association between antibiotic
exposure in pregnancy and CD in the offspring. Although
this may be reassuring, our study does not rule out a
modestly excess risk of CD in children to mothers
who were treated with antibiotics during pregnancy.
A strength of this study is its prospective design, where
data on antibiotic exposure in pregnancy were collected
before CD diagnosis, eliminating the risk of recall bias. We
also used prospectively collected data on infant feeding
and infectious diseases during the child’s first year of
life. Infections were measured through concurrent parent-
reporting, and not through patient charts, because mostSwedish infants with minor infections do not seek medical
advice. Although, the infections were not recorded
using standardized self-reporting criteria we do not
suspect this potential risk of misclassification to be
differential between children exposed/unexposed to
antibiotics in pregnancy.
Similar to other birth-cohort studies [36,37], the current
study suffers from attrition. Half of the population
entering at birth completed the 1-year-diaries, and
there was a slight underrepresentation of parents with
foreign origin and low education [38]. However, this
should not influence the risk estimates if the association
between maternal antibiotic exposure and risk of offspring
CD is independent of education status. We are not aware
of any study indicating that education modifies the risk
factors of CD, even if socioeconomic status per se may be
linked to the risk of CD [39,40].
Of greater concern is the limited statistical power of this
study and the correspondingly increased risk of type 2
error (i.e. to erroneously accept a false null hypothesis).
Additionally, we have not been able to screen the ABIS
cohort for CD, and our patients consist of children
with clinically diagnosed CD. The baseline CD preva-
lence of 0.5% (46 out of 8729 children) is therefore
considerably lower than the estimated 2% prevalence
of screening-detected CD in Swedish children [41] (in
our study corresponding to 175 children). However,
false-negative CD in our control group (<2% [41])
should not affect our risk estimates. Further, we do
not expect risk factors to differ between children with
or without symptoms (meriting investigation for CD).
Unfortunately we lack data on clinical phenotype and
were unable to examine if intrauterine antibiotic exposure
is linked to a certain type of CD.
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retrospectively (at childbirth) and we did not have data on
the specific date of the antibiotic treatment or on intrapar-
tum antibiotics. Speculatively, antibiotic treatment during
the perinatal period may have a more profound impact on
infant gut colonization, as compared with antibiotic treat-
ment early in pregnancy [11]. Additionally, we largely lack
data on type of antibiotic agent, its dosage, duration of
treatment as well as the indication for treatment, which all
influence the mother’s microbiota, and that of the offspring
[42]. The lacking specificity regarding type of antibiotic
exposure may also have contributed to an increased risk of
a type 2 error. The type of antibiotic used by the mother
should also be linked to the type of infections she experi-
enced during pregnacy and her inflammatory status that
per se may also influence fetal immune programming and
risk of autoimmune disease in the offspring.
It is well-established that the postnatal intestinal micro-
biota influences the maturation of the intestinal immune
system and that individuals with CD, or with an increased
genetic risk of developing CD, have an imbalanced
intestinal microbiota, which may potentially enhance the
inflammatory response elicited by gluten [9,43-45]. Animal
studies suggest that the intestinal dysbiosis associated
with CD may, in the presence of gliadin, increase the
permeability of the small-intestine [9] and enable epithelial
translocation of gliadin that may trigger CD [9,46].
Although the current study lacks evidence for a prenatal
association between antibiotics and CD, our results do not
refute the hypothesis that the early intestinal microbiota
affects CD development.
Postnatal microbial exposure is likely to play a greater
role in immune maturation and thereby CD development
as compared with prenatal microbial exposure [35]. Still,
vast amount of data suggest that pregnancy is a critical time
for immune development and epigenetic models of allergic
outcomes suggest that foetal immune development may be
influenced by epigenetic modifications from microbial
products [35]. In addition, several epidemiological studies
have shown that prenatal exposures to antibiotics are asso-
ciated with the development of childhood asthma, a disease
that shares potential etiological traits with CD [19-21].
Conclusions
This study found no statistically significant association
between maternal use of antibiotics during pregnancy
and CD in the offspring. This lack of association may either
be true or due to limited statistical power.
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